

# CITATION REPORT

List of articles citing

**Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group**

**DOI: 10.1016/0895-7061(96)00037-4  
American Journal of Hypertension, 1996, 9, 342-60.**

**Source:** <https://exaly.com/paper-pdf/26770677/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
417	Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. <b>1996</b> , 347, 1061-5		190
416	Safety aspects of treatment with lacidipine--a slow-onset, long-acting calcium antagonist. <b>1996</b> , 5, 241-9		10
415	Safety of calcium antagonists: dissecting the evidence. <b>1996</b> , 78, 19-23		37
414	Calcium channel blockers and hypertension: 1. New trials. <b>1996</b> , 31, 125-8, 133-6		3
413	Efficacy and Safety of Nifedipine Coat-Core versus Amlodipine in Patients With Mild to Moderate Essential Hypertension: Comparison of 24-Hour Mean Ambulatory Diastolic Blood Pressure. <b>1997</b> , 2, 77-84		7
412	A personal view of the controversy regarding the use of calcium channel blockers in hypertension. <b>1997</b> , 15, S41-S46		1
411	Clinical implications of the World Health Organization-International Society of Hypertension statement on calcium antagonists. <b>1997</b> , 15, 1197-200		8
410	Hypertension: stalking the silent killer. <b>1997</b> , 101, 116-21		7
409	Slowly acting calcium antagonists and their merits. <b>1997</b> , 6, 78-80		15
408	Calcium-antagonist controversy: the long and short of it?. <b>1997</b> , 349, 585-6		11
407	Hypertension. <b>1997</b> , 2, 8-21		
406	Management of lipid disorders in the elderly. <b>1997</b> , 10, 444-62		11
405	Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. <b>1997</b> , 19, 779-91		35
404	Cholesterol screening should be targeted. <b>1997</b> , 102, 26-30		8
403	An approach to treating hypertension. <b>1997</b> , 1, 61-2		
402	Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. <b>1997</b> , 349, 594-8		142
401	Potential Role of Angiotensin-Converting Enzyme Inhibition in Myocardial Ischemia and Current Clinical Trials. <b>1997</b> , 20, II-58		4

400	The calcium channel blocker controversy in 1997. <b>1997</b> , 27, 330-5	4
399	Improved endothelial function with angiotensin-converting enzyme inhibitors. <b>1997</b> , 79, 29-32	17
398	Cardiac effects of calcium antagonists in systemic hypertension. <b>1997</b> , 79, 39-46; discussion 47-8	26
397	Effects of calcium antagonists on insulin sensitivity and other metabolic parameters. <b>1997</b> , 79, 24-8; discussion 47-8	51
396	Systolic hypertension in the elderly. <b>1997</b> , 22, 405-43	2
395	When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?. <b>1997</b> , 18, 613-20; discussion 661-6	44
394	Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients. <b>1998</b> , 25, 572-6	34
393	Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. <b>1998</b> , 19, 370-90	75
392	Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. <b>1998</b> , 82, 9R-14R	140
391	Calcium antagonists and the diabetic patient: a response to recent controversies. <b>1998</b> , 82, 40R-41R	39
390	Calcium antagonists and renal disease. <b>1998</b> , 54, 1771-84	19
389	Selective imidazoline receptor agonists for metabolic syndrome. <b>1998</b> , 351, 152-3	30
388	Anti-hypertensive therapy reduced the incidence of stroke in older patients with isolated systolic hypertension. <b>1998</b> , 2, 22	
387	Clinical trials of reducing low-density lipoprotein concentrations. <b>1998</b> , 27, 585-95, viii-ix	8
386	Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. <b>1998</b> , 135, 406-13	11
385	Lessons from hypertension trials. <b>1998</b> , 104, 50S-53S	17
384	Antihypertensive efficacy of treatment regimens used in Veterans Administration hypertension clinics. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. <b>1998</b> , 31, 771-9	26
383	Calcium-channel blockers for hypertension--uncertainty continues. <b>1998</b> , 338, 679-81	76

382	Pharmacotherapy for hypertension in the elderly. <b>2000</b> , CD000028	27
381	Renin-angiotensin-aldosterone-kinin system influences on diabetic vascular disease and cardiomyopathy. <b>1998</b> , 24, 412-22	9
380	British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity. <b>1999</b> , 319, 589-90	8
379	Assessment and control for confounding by indication in observational studies. <b>1999</b> , 47, 749-54	231
378	Safety of nifedipine in angina pectoris: a meta-analysis. <b>1999</b> , 33, 24-31	31
377	Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. <b>1999</b> , 26, 500-4	15
376	Efficacy of treating hypertension in women. <b>1999</b> , 14, 718-29	29
375	Treatment of diabetic patients with hypertension. <b>1999</b> , 1, 225-31	7
374	Controversies surrounding the treatment of the hypertensive patient with diabetes. <b>1999</b> , 1, 512-20	9
373	The World Health Organization--International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. <b>1999</b> , 1, 346-56	6
372	Special considerations in the therapy of diabetic hypertension. <b>1999</b> , 41, 461-70	12
371	Current status of calcium channel blockers in patients with cardiovascular disease. <b>1999</b> , 24, 236-340	11
370	Glycemic control and cardiovascular disease in type 2 diabetes: a review. <b>1999</b> , 15, 197-204	13
369	Alpha 1-blockers in hypertension. <b>1999</b> , 15, 95-103	11
368	Which drug for treatment of hypertension?. <b>1999</b> , 353, 604-5	24
367	Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. <b>1999</b> , 60, 228-236	8
366	Hypertension in the elderly. <b>1999</b> , 17, 79-92, viii	11
365	Hypertension and diabetes: current issues. <b>1999</b> , 138, S400-5	9

- 364 Alpha-adrenergic blocking drugs in clinical medicine. **1999**, 39, 7-16 13
- 363 Measuring blood pressure and treating hypertension in (frail) older people. **1999**, 47, 373-4
- 362 Calcium channel blockers - the effect on renal changes in clinical and experimental diabetes: an overview. **2000**, 15, 581-5 6
- 361 Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. **2000**, 132, 780-7 66
- 360 Pharmacotherapy for hypertension in women of different races. *The Cochrane Library*, **2000**, CD002146 5.2 6
- 359 Is hypercholesterolemia a risk factor and should it be treated in the elderly?. **2000**, 14, 347-56 11
- 358 Treatment of hypertension in patients with type-2 diabetes mellitus. **2000**, 18, 1345-6 4
- 357 Large multicentre hypertension trials. **2000**, 9, 285-92
- 356 Nifedipine and mortality risk in the elderly: relevance of drug formulation, dose and duration. **2000**, 9, 11-23 10
- 355 Risk factor clustering in hypertensive patients: impact of the reports of NCEP-II and second joint task force on coronary prevention on JNC-VI guidelines. **2000**, 248, 203-10 18
- 354 Debate: Does it matter how you lower blood pressure?. **2000**, 1, 69-71
- 353 Diabetes mellitus and coronary heart disease--from prevention to intervention: Part I. **2000**, 30, 351-9 8
- 352 Pharmacotherapy in congestive heart failure: reflections on diabetes, clinical trials, and cardiovascular morbidity and mortality. **2000**, 6, 110-114
- 351 Practical guidelines for multiplicity adjustment in clinical trials. **2000**, 21, 527-39 169
- 350 The anti-ischemic potential of angiotensin-converting enzyme inhibition: insights from the heart outcomes prevention evaluation trial. **2000**, 23, IV9-14 12
- 349 Coronary heart disease prevention As the primary goal in contemporary trials in the treatment of hypertension. **2000**, 2, 418-20 1
- 348 Critical appraisal of the JNC VI, WHO/ISH and BHS guidelines for essential hypertension. **2000**, 1, 675-82 13
- 347 Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. **2000**, 343, 580 7

346	To block the renin system or the calcium channel in hypertension--where do we stand?. <b>2000</b> , 1, 325-7		
345	ACE inhibitors in hypertension: still a shortage of evidence. <b>2000</b> , 1, 117-8		1
344	The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). <b>2000</b> , 1, 328-35		103
343	Women in clinical trials--a portfolio for success. <b>2000</b> , 343, 505-6		11
342	What does STOP-2 tell us about management of hypertension?. <b>2000</b> , 355, 651; author reply 653		
341	HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation. <b>2000</b> , 355, 246-7		15
340	Selection of initial antihypertensive drug therapy. <b>2000</b> , 356, 1942-3		23
339	Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. <b>2000</b> , 356, 1949-54		290
338	Management of Hypertension in Patients with Diabetes Mellitus. <b>2000</b> , 7, 267-288		2
337	Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. <b>2000</b> , 36, 780-9		179
336	Heart disease in women. <b>2000</b> , 27, 741-66;vii		14
335	Hypertension. <b>2001</b> , 28, 321-31, vii		
334	Choosing initial antihypertensive drug therapy for the uncomplicated hypertensive patient. <i>Journal of Clinical Hypertension</i> , <b>2001</b> , 3, 37-44	2-3	4
333	Angiotensin-converting enzyme inhibitors. <b>2001</b> , 56, 13-75		44
332	Cardiovascular protection and blood pressure reduction: a meta-analysis. <b>2001</b> , 358, 1305-15		753
331	Pharmacology and clinical experience with simvastatin. <b>2001</b> , 2, 153-63		20
330	What is the optimal blood pressure in patients with diabetes mellitus?. <b>2001</b> , 1, 173-7		2
329	Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy?. <b>2001</b> , 10, 617-24		32

328	High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. <b>2001</b> , 19, 2063-70	190
327	Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors. <b>2001</b> , 11 Suppl 1, 85-95	29
326	Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. <b>2001</b> , 19, 1139-47	195
325	Coronary heart disease in African Americans. <b>2001</b> , 3, 97-108	116
324	Diabetes: statins, fibrates, or both?. <b>2001</b> , 3, 19-28	18
323	The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection?. <b>2001</b> , 3, 289-96	2
322	Lessons learned from prematurely terminated clinical trials. <b>2001</b> , 3, 360-6	2
321	A new era in hypertension research: discussing the findings of ALLHAT. <b>2001</b> , 2, 249-250	4
320	Comments on ALLHAT and doxazosin. <b>2001</b> , 2, 254-256	7
319	Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?. <b>2001</b> , 2, 257-259	3
318	Calcium antagonists in diabetic hypertension. <b>2001</b> , 3, 311-8	0
317	General practitioner participation in the second Australian National Blood Pressure Study (ANBP2). <b>2001</b> , 28, 663-7	15
316	The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases. <b>2001</b> , 10, 497-508	28
315	Surrogate endpoints: the debate goes on. <b>2001</b> , 10, 493-6	9
314	Monitoring clinical trials with multiple arms. <b>2001</b> , 57, 892-8	26
313	Developing a clinical strategy for cholesterol management in an era of unanswered questions. <b>2001</b> , 88, 25F-30F	2
312	Ongoing clinical trials of statins. <b>2001</b> , 88, 36F-40F	16
311	Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2001</b> , 22, 29-41	22

310	The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience. <b>2001</b> , 22, 659-73	36
309	Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2001</b> , 22, 674-86	33
308	Pharmacotherapy in congestive heart failure. Prematurely terminated clinical trials and their application to cardiovascular medicine. <b>2001</b> , 7, 265-271	3
307	Management of coronary heart disease risk factors and progression with calcium channel blockers. <b>2001</b> , 21, 195S-208S	2
306	Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2001</b> , 24, 654-8	30
305	Do arterial effects of antihypertensive drugs depend on subject's serum cholesterol?. <b>2001</b> , 38, 520-8	4
304	Ongoing clinical trials in systemic hypertension. <b>2001</b> , 10, 2031-7	2
303	Baseline Characteristics and Early Blood Pressure Control in the CONVINCe Trial. <b>2001</b> , 37, 12-18	156
302	Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2001</b> , 37, 19-27	87
301	Blood pressure control and benefits of antihypertensive therapy: does it make a difference which agents we use?. <b>2001</b> , 38, 537-42	31
300	The management of the elderly with hypertension. <b>2001</b> , 2, 11-3	
299	Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. <b>2001</b> , 38, 953-7	54
298	Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. <b>2001</b> , 37, 1047-52	664
297	Treating hypertension in the elderly. <b>2001</b> , 10, 355-65	4
296	The SCOPE trial. Study on Cognition and Prognosis in the Elderly. <b>2002</b> , 3, 61-2	9
295	Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management. <b>2002</b> , 3, 96-102	3
294	Regression of left ventricular hypertrophy: hoping for a longer life. <b>2002</b> , 3, 141-4	4
293	Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. <b>2002</b> , 2, 309-17	43



292	Doxazosin, an inferior antihypertensive agent?. <b>2002</b> , 16, 375-7		4
291	Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. <b>2002</b> , 3, 72-8		26
290	Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension. <b>2002</b> , 3, 79-89		9
289	Smoking, blood pressure and cardiovascular risk. <b>2002</b> , 20, 1699-701		4
288	Quality of life on randomized treatment for isolated systolic hypertension: results from the Syst-Eur Trial. <b>2002</b> , 20, 2069-79		21
287	Biobehavioral approaches to the treatment of essential hypertension.. <b>2002</b> , 70, 569-589		33
286	The treatment of hypertension in adult patients with diabetes. <b>2002</b> , 25, 134-47		221
285	Vascular and cardiac benefits of angiotensin receptor blockers. <b>2002</b> , 113, 409-18		108
284	Premature termination of clinical trials--lessons learned. <i>Journal of Clinical Hypertension</i> , <b>2002</b> , 4, 219-252.3		4
283	Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). <i>Journal of Clinical Hypertension</i> , <b>2002</b> , 4, 393-404	2.3	720
282	Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. <b>2002</b> , 62, 339-85		13
281	Antihipertensivos clnicos o modernos en el tratamiento de la hipertensi arterial: debe seguir existiendo controversia en su elecci?. <b>2002</b> , 28, 560-572		0
280	Hypertension and diabetes. <b>2002</b> , 18 Suppl 1, s48-57		11
279	Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 1997-2000. <b>2002</b> , 24, 1451-62		8
278	Hipertensi arterial y diabetes. Avances teraputicos. <b>2002</b> , 99, 73-80		
277	Prevention of cardiovascular diseases. Coronary artery disease, congestive heart failure, and stroke. <b>2002</b> , 18, 463-83, vii		9
276	Anlisis de la prescripci de hipolipidemiantes en un centro de Atenci Primaria. <b>2002</b> , 28, 127-130		2
275	Improving the managed care of hypertension with angiotensin II antagonists. <b>2002</b> , 323, 25-33		4

274	Justifying lipid-lowering therapy in persons $\geq 65$ years of age. <b>2002</b> , 90, 1330-2		5
273	Doxazosin and congestive heart failure. <b>2002</b> , 8, 178-84		12
272	Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. <b>2002</b> , 50, 416-23		48
271	Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. <b>2002</b> , 3, 10		51
270	Blood pressure control in patients with type 2 diabetes and hypertension. <b>2002</b> , 4, 81-8		1
269	Lipid lowering: another method of reducing blood pressure?. <b>2002</b> , 16, 753-60		33
268	Drugs targeting the renin-angiotensin-aldosterone system. <b>2002</b> , 1, 621-36		326
267	REFERENCES. <b>2003</b> , 41, S77-S91		
266	Arterial hypertension and ischaemic stroke. <b>2003</b> , 107, 241-51		34
265	The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. <b>2003</b> , 20, 607-21		60
264	[Design and conclusions of the ALLHAT study]. <b>2003</b> , 56, 1034-5; author reply 1035		
263	Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. <i>Journal of Clinical Hypertension</i> , <b>2003</b> , 5, 66-75	2.3	24
262	Optimal treatment of hypertension and cardiovascular risk reduction in African Americans: treatment approaches for outpatients. <i>Journal of Clinical Hypertension</i> , <b>2003</b> , 5, 18-25	2.3	5
261	Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>Journal of Clinical Hypertension</i> , <b>2003</b> , 5, 377-84	2.3	12
260	A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. <b>2003</b> , 348, 583-92		903
259	Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications. <b>2003</b> , 41, 1006-9		13
258	Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2003</b> , 42, 239-46		209
257	Multiple Analyses and Multiple Endpoints. <b>2003</b> , 105-154		

256	Comments on the renal aspects of the ALLHAT study. <b>2003</b> , 21, 235-6	3
255	ALLHAT: is the final answer in?. <b>2003</b> , 5, 171-5	2
254	Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. <b>2003</b> , 21, 1055-76	365
253	Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm. <b>2003</b> , 14, 593-7	1
252	Pharmacogenomics of hypertension. <b>2003</b> , 12, 61-70	25
251	What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia. <b>2003</b> , 18, 389-95	
250	International Society of Hypertension (ISH). <b>2003</b> , 21, 651-663	36
249	Lessons learned from clinical trials: a roundtable discussion. <b>2003</b> , 2, 55-9	
248	Subgroups III: Confirmatory Analyses. <b>2003</b> , 303-340	
247	Multiple Analyses and Multiple Treatment Arms. <b>2003</b> , 341-358	
246	Drug Therapy for Hypertension: Does ALLHAT Alter our Approach?. <b>2003</b> , 38, 533-543	
245	New hypertension trials: what do the results mean for the elderly?. <b>2004</b> , 19, 69-72	
244	The effects of an open design on trial participant recruitment, compliance and retention--a randomized controlled trial comparison with a blinded, placebo-controlled design. <b>2004</b> , 1, 490-8	58
243	Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. <b>2004</b> , 160, 1152-8	211
242	ALLHAT-LLT: questions, questions, and more questions (and some answers). <b>2004</b> , 6, 375-80	3
241	Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study. <b>2004</b> , 6, 106-10	35
240	Balancing commercial and public interests. <b>2004</b> , 5, 6	2
239	ALLHAT: a critical assessment. <b>2004</b> , 13, 75-9	7

238	Comparisons of hypertension-related costs from multinational clinical studies. <b>2004</b> , 22, 1001-14		21
237	Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <b>2004</b> , 148, 747-54		57
236	Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. <i>Journal of Clinical Hypertension</i> , <b>2004</b> , 6, 116-25	2.3	49
235	ALLHAT and its implications in the diabetic population. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2004</b> , 1, 43-47		
234	WITHDRAWN: Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks. <i>The Cochrane Library</i> , <b>2007</b> , CD005183	5.2	2
233	Temporal changes in the control of blood pressure in an older Australian population. <b>2005</b> , 19, 691-6		10
232	Psychosocial work characteristics predict cardiovascular disease risk factors and health functioning in rural women: the Wisconsin Rural Women's Health Study. <b>2005</b> , 21, 295-302		16
231	Acute coronary syndromes in black Americans: is treatment different? Should it be?. <b>2005</b> , 7, 249-54		6
230	The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2005</b> , 340-351		
229	Cooperative Heart Disease Trials. <b>2005</b> ,		
228	Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2005</b> , 112, 3654-60; discussion 3666		62
227	Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. <b>2005</b> , 111, 3374-83		116
226	Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <b>2005</b> , 10, 729-45		7
225	Benefits of Diuretic-Based Low-Cost Antihypertensive Therapy. <b>2005</b> , 12, 73-78		
224	Statins and fibrates for preventing melanoma. <i>The Cochrane Library</i> , <b>2005</b> , CD003697	5.2	25
223	Prescribing patterns of diuretics in multi-drug antihypertensive regimens. <i>Journal of Clinical Hypertension</i> , <b>2005</b> , 7, 81-7; quiz 88-9	2.3	4
222	Sitting on the evidence: what is the proper patient position for the office measurement of blood pressure?. <i>Journal of Clinical Hypertension</i> , <b>2005</b> , 7, 365-6	2.3	2
221	Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). <i>Journal of Clinical Hypertension</i> , <b>2005</b> , 7, 264-73	2.3	58

220	Doxazosin GITS versus standard doxazosin in mild to moderate hypertension. <b>2005</b> , 101, 97-104		5
219	Systolic hypertension: an overview. <b>2005</b> , 149, 769-75		9
218	A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. <b>2006</b> , 24, 387-400		13
217	Evidence relating dietary sodium to cardiovascular disease. <b>2006</b> , 25, 256S-261S		30
216	A simple and valid tool distinguished efficacy from effectiveness studies. <b>2006</b> , 59, 1040-8		148
215	Renoprotective effects of renin-angiotensin-system inhibitors [Authors' reply]. <b>2006</b> , 367, 900-902		19
214	Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. <b>2006</b> , 26, 529-39		9
213	Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>Journal of Clinical Hypertension</i> , <b>2006</b> , 8, 649-56; quiz 657-8	2.3	35
212	Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. <b>2006</b> , 67, 225-31		7
211	Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril. <b>2006</b> , 2006, 60-62		1
210	Mechanisms of target organ damage caused by hypertension: therapeutic potential. <b>2006</b> , 111, 81-98		103
209	Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall. <b>2006</b> , 6, 47		13
208	Progression of renal disease—can we forget about inhibition of the renin-angiotensin system? Authors' reply. <b>2006</b> , 21, 2352-2353		3
207	Pitfalls in blood pressure measurement in daily practice. <b>2006</b> , 23, 20-7		20
206	Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care?. <b>2006</b> , 48, 1-7		61
205	Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies. <b>2006</b> , 48, 359-61		14
204	Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <b>2006</b> , 113, 2201-10		114
203	Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. <b>2006</b> , 48, 374-84		128

202	The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). <b>2006</b> , 114, 2850-70		286
201	Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. <b>2007</b> , 7, 112-22		50
200	Understanding the quality chasm for hypertension control in diabetes: a structured review of "co-maneuvers" used in clinical trials. <b>2007</b> , 20, 469-78		12
199	Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. <b>2007</b> , 5, 444-52		53
198	Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. <b>2007</b> , 50, 854-61		45
197	The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. <b>2007</b> , 153, 42-53		58
196	Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. <b>2007</b> , 153, 54-8		24
195	Dependence, hyper-dependence and hypothesis testing in clinical trials. <b>2007</b> , 28, 68-78		5
194	Hypertension patients participating in trials differ in many aspects from patients treated in general practices. <b>2007</b> , 60, 330-5		24
193	Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study. <b>2007</b> , 71, 735-45		13
192	Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>Journal of Clinical Hypertension</i> , <b>2008</b> , 10, 751-60	2.3	66
191	Management of high blood pressure in clinical practice: perceptible qualitative differences in approaches utilized by clinicians. <i>Journal of Clinical Hypertension</i> , <b>2008</b> , 10, 822-9	2.3	6
190	Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2008</b> , 168, 207-17		80
189	Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. <b>2008</b> , 117, 2691-704; discussion 2705		40
188	Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2008</b> , 31, 353-60		87
187	Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. <b>2008</b> , 118, 2259-67		152
186	Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. <b>2008</b> , 18, 651-6		30
185	ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. <b>2009</b> , 169, 832-42		81

184	National heart, lung, and blood institute-initiated program "interventions to improve hypertension control rates in African Americans": background and implementation. <b>2009</b> , 2, 236-40		7
183	Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?. <i>Journal of Clinical Hypertension</i> , <b>2009</b> , 11, 466-74	2.3	15
182	Comparative effectiveness research: an approach to avoiding "overgeneralized medicine". <b>2009</b> , 2, 444-5		1
181	Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. <b>2009</b> , 31, 1116-23		76
180	Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project. <b>2009</b> , 6, 329-43		17
179	Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT). <b>2009</b> , 158, 948-55		13
178	Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). <b>2009</b> , 54, 2023-31		131
177	First-line drugs for hypertension. <i>The Cochrane Library</i> , <b>2009</b> , CD001841	5.2	120
176	Pharmacotherapy for hypertension in the elderly. <i>The Cochrane Library</i> , <b>2009</b> , CD000028	5.2	107
175	Diabetes and cardiovascular disease prevention in older adults. <b>2009</b> , 25, 607-41, vii-viii		34
174	The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study. <b>2009</b> , 19, 338-44		17
173	Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. <b>2009</b> , 19, 415-21		17
172	ALLHAT: still providing correct answers after 7 years. <b>2010</b> , 25, 355-65		13
171	Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. <b>2010</b> , 28, 2076-83		21
170	The assessment, serial evaluation, and subsequent sequelae of acute kidney injury (ASSESS-AKI) study: design and methods. <b>2010</b> , 11, 22		107
169	Comparative effectiveness research: Policy context, methods development and research infrastructure. <b>2010</b> , 29, 1963-76		104
168	Impact of ALLHAT publication on antihypertensive prescribing patterns in Regione Emilia-Romagna, Italy. <b>2010</b> , 35, 55-61		9
167	The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. <b>2010</b> , 87, 351-5		38

166 Baseline Assessment. **2010**, 169-182

165	Calcium channel blockers versus other classes of drugs for hypertension. <i>The Cochrane Library</i> , <b>2010</b> , CD003654	5.2	36
164	Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). <b>2011</b> , 124, 1811-8		39
163	Comparative effectiveness: the fourth hurdle in drug development and a role for clinical pharmacology. <b>2011</b> , 89, 151-6		13
162	Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. <b>2011</b> , 10, 22		124
161	Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. <b>2012</b> , 59, 926-33		66
160	The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research. <b>2012</b> , 9, 436-46		125
159	Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. <b>2012</b> , 7, 989-1002		64
158	Pathophysiologic therapeutic targets in hypertension: a cardiological point of view. <b>2012</b> , 16, 179-93		9
157	Evaluation of pharmaceutical drug information brochures in the Emirate of Abu Dhabi (United Arab Emirates). <b>2012</b> , 3, 57-62		3
156	Impact of the number of blood pressure measurements on blood pressure classification in US adults: NHANES 1999-2008. <i>Journal of Clinical Hypertension</i> , <b>2012</b> , 14, 751-9	2.3	47
155	Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. <b>2012</b> , 164, 925-31.e2		12
154	Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. <b>2012</b> , 7, e34217		32
153	Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Journal of Clinical Hypertension</i> , <b>2012</b> , 14, 20-31	2.3	33
152	Approaches to data analyses of clinical trials. <b>2012</b> , 54, 330-4		16
151	Generic drugs for hypertension: are they really equivalent?. <b>2013</b> , 15, 340-5		6
150	Longitudinal changes in dietary fat intake and associated changes in cardiovascular risk factors in adults with type 2 diabetes: the ACCORD trial. <b>2013</b> , 100, 61-8		3
149	How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?. <b>2013</b> , 32, 884-97		3



148	Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. <b>2013</b> , 10, 807-27		20
147	Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. <b>2013</b> , 61, 977-86		31
146	Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT. <b>2013</b> , 2013, 578578		12
145	RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. <b>2013</b> , 13, 330-4		11
144	Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). <i>Journal of Clinical Hypertension</i> , <b>2013</b> , 15, 542-54	2.3	21
143	Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT. <i>Journal of Clinical Hypertension</i> , <b>2013</b> , 15, 825-32	2.3	5
142	Efficacy of initiating therapy with amlodipine and hydrochlorothiazide or their combination in hypertensive Nigerians. <b>2013</b> , 35, 620-7		5
141	Cooperative Heart Disease Trials. <b>2014</b> ,		
140	High incarceration rates among black men enrolled in clinical studies may compromise ability to identify disparities. <b>2014</b> , 33, 848-55		14
139	The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study. <b>2014</b> , 5, 210		9
138	Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. <b>2014</b> , 179, 996-1005		32
137	Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <b>2014</b> , 64, 1012-21		152
136	Impaired fasting glucose and body mass index as determinants of mortality in ALLHAT: is the obesity paradox real?. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 451-8	2.3	15
135	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. <i>The Cochrane Library</i> , <b>2014</b> , CD007784	5.2	66
134	Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study. <b>2014</b> , 24, 556-63		8
133	The relationship between childhood BMI and adult serum cholesterol, LDL, and ankle brachial index. <b>2014</b> , 12, 33-9		4
132	What can comparative effectiveness research contribute to integrative health in international perspective?. <b>2014</b> , 20, 874-80		5
131	Formation of community-based hypertension practice networks: success, obstacles, and lessons learned. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 393-7	2.3	0

130	Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <i>Journal of Clinical Hypertension</i> , <b>2014</b> , 16, 323-30	2.3	43
129	Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation. <b>2014</b> , 45, 1287-95		96
128	Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. <b>2014</b> , 8, 808-19		12
127	Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. <b>2014</b> , 29, 1475-83		22
126	Protein phosphatase 1 inhibitor-1 deficiency reduces phosphorylation of renal NaCl cotransporter and causes arterial hypotension. <b>2014</b> , 25, 511-22		53
125	Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. <b>2014</b> , 32, 1503-13; discussion 1513		28
124	The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women's Health Initiative randomized controlled trials. <b>2014</b> , 32, 2071-81; discussion 2081		17
123	Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. <b>2015</b> , 163, 329-38		178
122	Adaptive designs for comparative effectiveness research trials. <b>2015</b> , 32, 36-44		
121	Determinants of discrepancies in detection and comparison of the prognostic significance of left ventricular hypertrophy by electrocardiogram and cardiac magnetic resonance imaging. <b>2015</b> , 115, 515-22		48
120	Genetics of resistant hypertension: a novel pharmacogenomics phenotype. <b>2015</b> , 17, 583		15
119	Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. <b>2015</b> , 19, 247-53		11
118	Cooperative Heart Disease Trials Sponsored by the National Heart, Lung, and Blood Institute (NHLBI). <b>2016</b> , 1-19		
117	Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <b>2016</b> , 10, 930-938.e9		10
116	Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity. <b>2016</b> , 11, 355-74		40
115	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. <b>2016</b> , 9, 213-21		8
114	Variability May Be the "Law of Life," but Blood Pressure Variability May Forebode a Shorter Life. <b>2016</b> , 67, 830-3		3
113	Pathophysiological Mechanisms and Correlates of Therapeutic Pharmacological Interventions in Essential Arterial Hypertension. <b>2017</b> , 956, 37-59		7

112	The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <b>2016</b> , 68, 39-45		60
111	The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study. <b>2016</b> , 30, 549-54		10
110	Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. <b>2016</b> , 11, 471-80		33
109	Randomized Controlled Trials. <b>2016</b> , 13-25		2
108	Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]). <b>2016</b> , 117, 105-15		7
107	Bayesian analysis of multi-type recurrent events and dependent termination with nonparametric covariate functions. <b>2017</b> , 26, 2869-2884		8
106	Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. <i>American Journal of Hypertension</i> , <b>2017</b> , 30, 914-922	2-3	28
105	Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. <b>2017</b> , 177, 955-965		88
104	Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). <b>2017</b> , 70, 94-102		12
103	Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. <b>2017</b> , 109, 172-181		2
102	Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. <b>2017</b> , 130, 439-448.e9		7
101	Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). <b>2017</b> , 48, 3078-3085		2
100	Relationship Between Visit-to-Visit Blood Pressure Variability (BPV) and Kidney Function in Patients with Hypertension. <b>2017</b> , 42, 697-707		7
99	University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (morning panel discussion). <b>2017</b> , 14, 441-450		3
98	Risk stratification of sudden cardiac death in hypertension. <b>2017</b> , 50, 798-801		11
97	Pharmacotherapy for hypertension in adults aged 18 to 59 years. <i>The Cochrane Library</i> , <b>2017</b> , 8, CD008276		22
96	Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). <b>2017</b> , 10,		4
95	Research in Pediatrics. <b>2017</b> , 573-586		

94	Bayesian regression model for recurrent event data with event-varying covariate effects and event effect. <b>2018</b> , 45, 1260-1276		3
93	The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications. <i>American Journal of Hypertension</i> , <b>2018</b> , 31, 609-614	2,3	5
92	First-line drugs for hypertension. <i>The Cochrane Library</i> , <b>2018</b> , 4, CD001841	5.2	74
91	Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. <b>2018</b> , 110, 343-351		1
90	Are Synthetic Data Derivatives the Future of Translational Medicine?. <b>2018</b> , 3, 716-718		9
89	Antihypertensive Drug Therapy in Patients of African and South Asian Ethnicity: A Systematic Review. <b>2018</b> , 243-269		
88	Optimal medical treatment of hypertension in patients with coronary artery disease. <b>2018</b> , 16, 815-823		1
87	Peripheral Adrenergic Blockers. <b>2018</b> , 222-229		
86	Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT. <b>2019</b> , 8, e012277		25
85	Income Inequality and Hypertension Control. <b>2019</b> , 8, e013636		9
84	Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial. <b>2019</b> , 74, 1033-1040		14
83	Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study. <b>2019</b> , 42, 486-493		58
82	Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 451-459	2.3	10
81	Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. <b>2019</b> , 8, e011961		10
80	Pharmacotherapy for hypertension in adults 60 years or older. <i>The Cochrane Library</i> , <b>2019</b> , 6, CD000028	5.2	16
79	Association of Sustained Blood Pressure Control with Multimorbidity Progression Among Older Adults. <b>2020</b> , 68, 2059-2066		5
78	Pharmacological interventions for heart failure in people with chronic kidney disease. <i>The Cochrane Library</i> , <b>2020</b> , 2, CD012466	5.2	3
77	The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. <b>2020</b> , 38, 954-960		4

76	Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study. <b>2021</b> , 9, 100-111	1
75	Association of Sustained Blood Pressure Control with Lower Risk for High-Cost Multimorbidities Among Medicare Beneficiaries in ALLHAT. <b>2021</b> , 36, 2221-2229	1
74	Kidney, Cardiac, and Safety Outcomes Associated With $\beta$ -Blockers in Patients With CKD: A Population-Based Cohort Study. <b>2021</b> , 77, 178-189.e1	6
73	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. <b>2021</b> , 22, 558-570	15
72	Sustained SBP control and long-term nursing home admission among Medicare beneficiaries. <b>2021</b> , 39, 2258-2264	1
71	Data Monitoring in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Early Termination of the Doxazosin Treatment Arm. <b>2006</b> , 248-259	1
70	Sample Size. <b>2015</b> , 165-200	2
69	Baseline Assessment. <b>2015</b> , 201-214	1
68	Calcium Antagonists and Calcium Sensitizers. <b>2000</b> , 333-363	1
67	Hypertensive patients and diabetes: a high-risk population. <b>1998</b> , 32 Suppl 2, S1-8	4
66	Long-term morbidity and mortality trials with amlodipine. <b>1999</b> , 33 Suppl 2, S1-6	13
65	Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. <b>1997</b> , 52, 198-201	29
64	Analysis of the Risks Associated With Calcium Channel Blockade: Implications for the Obstetrician-Gynecologist. <b>1999</b> , 54, 179-182	2
63	Angiotensin converting enzyme inhibitors: first line therapy in patients with diabetic hypertension?. <b>1999</b> , 8, 333-4	2
62	Treatment of chronic hypertension for the prevention of stroke. <b>2003</b> , 96, 359-62	7
61	Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study. <b>2012</b> , 22, 355-66	13
60	Safety of nifedipine in patients with hypertension: a meta-analysis. <b>1997</b> , 30, 7-14	17
59	Safety of Nifedipine in Patients With Hypertension. <b>1997</b> , 30,	1

- 58 Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. **2011**, 6, e23609 20
- 57 Les inhibiteurs calciques dans les affections cardiovasculaires. **2000**, 59, 25-37 5
- 56 Calcium channel blockers versus other classes of drugs for hypertension. *The Cochrane Library*, **2021**, 10, CD003654 5.2 3
- 55 Scientific Basis for New Guidelines for the Treatment of Hypertension in Type 2 Diabetes. **2000**, 611-621
- 54 Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria. **2000**, 441-459 1
- 53 Blind Guides for Explorers: P Values, Subgroups and Data Dredging. **2000**, 251-266
- 52 Calcium Antagonists. **2000**, 148-166
- 51 Metabolic and Cardiovascular Factors Contributing to Hypertension in the Elderly. **2000**, 249-261
- 50 Evaluative and epidemiological approaches of ACE therapy. **2001**, 47-70
- 49 Antihypertonika. **2001**, 193-208
- 48 The Therapeutic Trials. **2001**, 162-184
- 47 Hypertension, Diabetes and the Heart. **2002**, 65-84
- 46 Hypertension in Type 2 Diabetes Mellitus. **2003**, 63-84 1
- 45 Inhibitors of the RAS: Evidence-Based Medicine. **2004**, 545-592
- 44  $\beta$ Adrenoceptor Blockers. **2005**, 660-668
- 43 Intervention in high risk groups: hypertension. **2005**, 865-892
- 42 Search Versus Research. **2006**, 37-62
- 41 Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). **2006**, 2006, 64-66

40 Does hypertension during pregnancy contribute to female metabolic syndrome?. **2006**, 12, 117-120

39 Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. **2007**, 2007, 75-77

38 Design of Outcome Studies. **2007**, 305-315

37 Hypertension and Stroke in Racial/Ethnic Groups. **2009**, 103-118

36 Pediatrics. **2009**, 497-507

35 The intensive control of blood pressure: possibilities of the combined therapy.. *Systemic Hypertension*, **2009**, 6, 22-27 1.6

34 Calcium channel blockers. **2011**, 258-263

33 The Durability of African American Hypertension as a Disease Category. **2012**, 83-106

32 Making Normal Populations and Making Difference in the Framingham and Jackson Heart Studies. **2012**, 52-82

31 Notes. **2012**, 197-224

30 BiDil. **2012**, 155-179

29 Thiazide Diuretics at a Nexus of Associations. **2012**, 131-154

28 Introduction. **2012**, 1-27

27 Conclusion. **2012**, 180-196

26 The Slavery Hypothesis beyond Genetic Determinism. **2012**, 107-130

25 Racial Preoccupations and Early Cardiology. **2012**, 28-51

24 Severity of carbohydrate metabolism disturbances, arterial hypertension stage, and lipid profile in patients with metabolic syndrome. **2012**, 11, 13-18 1

23 Design of Outcome Studies. **2013**, 237-243

22 ?????????Ca??? : ??????????????????????. **1997**, 5, 85-89

21 Hypertensive Patients and Diabetes. **1998**, 32, S1-S8 8

20 New Evidence on the Prevention of Cardiovascular Events in Hypertensive Patients with Type 2 Diabetes. **1998**, 32, S18-S23 10

19 New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. **1998**, 32 Suppl 2, S18-23 4

18 Management of Stable Angina Pectoris. **1999**, 19-39

17 The Glycemic Consequences of Antihypertensive Medications. **2015**, 935-948

16 Calcium channel blockers: more than 50 years on guard of health. *Systemic Hypertension*, **2015**, 12, 49-56. 1.6 0

15 Chapter 14: Comparative Effectiveness. **2017**,

14 Prevention of heart failure in hypertension [Disentangling the role of evolving left ventricular hypertrophy and blood pressure lowering: the ALLHAT study.

13 Modern Principles of Treatment of Uncontrolled Hypertension. *Rational Pharmacotherapy in Cardiology*, **2019**, 15, 736-741 0.5 2

12 Worsening of kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study.

11 Primary Hypertension. **2020**, 125-133

10 Association between aspirin use and cardiovascular outcomes in ALLHAT participants with and without chronic kidney disease: A post hoc analysis. *Journal of Clinical Hypertension*, **2021**, 23, 352-362 2.3 0

9 Diuretics and  $\beta$ Adrenergic Blockers in the Management of Hypertension in the Elderly. **2005**, 297-319

8 ALLHAT and its implications in the diabetic population. *Therapy: Open Access in Clinical Medicine*, **2004**, 1, 43-47

7 Diagnosis and treatment of high blood pressure. New directions and new approaches: 1999 Canadian recommendations for management of hypertension. *Canadian Family Physician*, **2000**, 46, 1479-84 0.9 1

6 Calcium channel blockers versus other classes of drugs for hypertension.. *The Cochrane Library*, **2022**, 1, CD003654 5.2 0

5 Counterfactual Phenotyping with Censored Time-to-Events. **2022**,



- 4 SMOC2 gene interacts with APOL1 in the development of end-stage kidney disease: A genome-wide association study. 9,
- 3 Role of  $\beta$ -blockers in the current management of hypertension. **2022**, 24, 1180-1186
- 2 Thiazide Diuretics and Fracture Risk: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
- 1 An estimation of physicochemical properties of heart attack treatment medicines by using molecular descriptor's. **2023**, 45, 20-29